| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects. (NCT07153146) | Protagonist Therapeutics, Inc. | 2025-10-07 |
| Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (NCT06033586) | Protagonist Therapeutics, Inc. | 2024-01-22 |
| A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (NCT05210790) | Protagonist Therapeutics, Inc. | 2022-04-01 |
| Pharmacokinetics of PN-232 in Healthy Volunteers (NCT04819620) | Protagonist Therapeutics, Inc. | 2021-05-13 |
| PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (NCT04767802) | Protagonist Therapeutics, Inc. | 2021-02-02 |
| Pharmacokinetics of PN-235 in Healthy Volunteers (NCT04621630) | Protagonist Therapeutics, Inc. | 2020-11-12 |
| Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers (NCT04516382) | Protagonist Therapeutics, Inc. | 2020-09-14 |
| PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC) (NCT04504383) | Protagonist Therapeutics, Inc. | 2020-08-05 |
| PTG-300 in Subjects With Hereditary Hemochromatosis (NCT04202965) | Protagonist Therapeutics, Inc. | 2020-03-19 |
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) (NCT04057040) | Protagonist Therapeutics, Inc. | 2019-10-01 |
| Safety Study for Beta Thalassemia Subjects on PTG-300 (NCT04054921) | Protagonist Therapeutics, Inc. | 2019-05-10 |
| Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia (NCT03802201) | Protagonist Therapeutics, Inc. | 2018-12-19 |